Compare PYXS & BZUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PYXS | BZUN |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | China |
| Employees | 56 | 6762 |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.2M | 159.3M |
| IPO Year | 2021 | N/A |
| Metric | PYXS | BZUN |
|---|---|---|
| Price | $2.75 | $2.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 534.1K | 420.1K |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,858,000.00 | N/A |
| Revenue This Year | N/A | $7.89 |
| Revenue Next Year | $7,043.98 | $6.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.97 | $2.07 |
| 52 Week High | $5.55 | $4.88 |
| Indicator | PYXS | BZUN |
|---|---|---|
| Relative Strength Index (RSI) | 79.98 | 52.47 |
| Support Level | $1.28 | $2.64 |
| Resistance Level | $3.89 | $2.81 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 98.25 | 12.39 |
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.